Compare Corning Incorporated (GLW) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs ResMed Inc. — how do they compare? Corning Incorporated trades at $157.78 (market cap $150.10B), while ResMed Inc. trades at $202.22 (market cap $28.80B). The key difference: Corning Incorporated is far larger — about 5.2× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.21%). Which is the better fit depends on your goals.
| GLW | RMD | |
|---|---|---|
Market Cap | $150.10B | $28.80B |
Sector | Technology | Health |
52-Week High | $255.79 | $293.73 |
52-Week Low | $52.97 | $182.82 |
Enterprise Value | $158.27B | $27.99B |
Dividend Yield | 0.64% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $187.68, up 2.36% today, with a neutral technical signal and bearish moving averages. Recent earnings beats and strong 2025 results, including $15.63B revenue and $1.60B net income, highlight fundamental strength. The stock has retreated from its June 2026 peak of $271.38, with analyst consensus pointing to a $210.10 price target. Key support lies at $185, with resistance at $191.
The outlook remains positive due to AI-driven optical communication demand and partnerships with NVIDIA and Amazon. Risks include market volatility and competitive pressures, but institutional sentiment is bullish with 54% buy ratings. Upside potential exists if the company maintains its earnings momentum and capitalizes on infrastructure spending trends.
ResMed (RMD) trades at $196.37, up 1.74% with strong fundamental performance including 27.44% net margins and consistent earnings beats. The company recently sold its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets. Technical indicators show bearish momentum despite oversold RSI conditions, while fundamentals demonstrate robust revenue growth from $5.15B to projected $5.5B in 2026.
RMD presents a compelling growth story with 40% analyst buy ratings and $245.88 consensus target suggesting 25% upside. Key risks include competitive pressures in medical technology and execution of strategic refocusing. The stock's current valuation at 19.15 P/E appears reasonable given earnings momentum and market leadership in sleep apnea treatment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
